Member Info for gjbrandon

@Chesh, working from my phone, so will check that out later and will have it corrected. Thank you in advance. Indeed the warrants were at 2p

@Chryslis
a) The reagents are used to identify any pathogen is the drinking or in fluent water from any source. They detect if the water is contaminated from up to 2,700 different types of contaminant. They do not identify what the pathogen is.

b) Aptamers are used to capture a specific target, such as a single or in the case of the area in each cartridge multiple pathogens. The problem is that you have to detect something that is 1/7000th thickness of a human hair. That is why the current process is the use of rtPCR back in a lab where to do so you need to convert the RNA to DNA and compare that to the known DNA code of SARS-CoV-2.

Using the RAWTest AI method we use a laser detection device to measure the captured molecule (pathogenic virus) take a digital image of this molecule and compare it to a dataset of samples, using AI to determine it is precisely the target pathogen. This takes as long as the Dataset runs its comparison. In the case of the bacteria we announced back in late 2019,it is under 4 seconds.

Aptamers capturing the target pathogen do not trigger any alert, it is the RAWTest and AI determination that does that.

Hope that is clearer.

@Chesh June 15th RNS https://www.londonstockexchange.com/news-article/SKIN/unsecured-loan-facility-agreement-with-cellulac/14576914

As Director, CEO and shareholder of Cellulac this £400,000 loan facility was provided to Integumen to draw down as they see fit for whatever purpose they need. (Lender)

@Newboy. That is just not in my nature :-) I prefer shareholders and potential shareholders to do the research and not just get soundbites on BB's. There is a lot out there on RNS, on the corporate and subsidiary website, on my twitter feed, in the 2019 Annual Report and clarifications on BB's.

Aptamers Group can supply to anyone they want to. I explained what we used previously (and that works) just that with Aptamers we don't have to use additional electronic elements. We could equally use Affimers or any antigen method of capture of the virus. RAWTest is what we do when the pathogen is captured and how we identify it. The Aptamers make it convenient to capture on the coating in our cartridges.

@trufflehound. Integumen will never reinvent a good solid wheel hat works. All the investment has been done on great technology that exists, so we collaborate, cooperate and revenue share. RAWTest was originally designed to use dielectrophoresis which is a technique to maneuvere cells using their polarity (physics) into the position where we could determine their spectrum digital signal for comparison with the datasets of AI we have on bacteria we originally were working on.

When we looked at viruses, which are much smaller than bacteria, we looked at a number of capture methods and we are constantly looking for others, which we will test in the future. However, the team at Aptamer Group had isolated Aptamers that have a good affinity to the spike of the protein of SARS-CoV-2 (A video of this can be seen here https://www.linkedin.com/feed/update/urn:li:activity:6678971478534324225/) so why even consider inventing something that works. Right?

So we worked with them for a couple of weeks to help them refine and redesign an Aptamer to meet our requirements and we entered into an agreement to use their virus capture aptamers as a coating on our nano-photonic surface. We don't care how the virus is captured, so long as it is captured. The detection and identification is in the use of our RAWTest miniaturisation of nano-photonics and AI to confirm that the virus that is captured is whatever pathogen we want to capture.

Hope that explains it but an illustration of how it works is here in the twitter image. https://twitter.com/gjbrandon/status/1275567638727528448?s=20

There is nothing to be confused about as pretty much everyone of you is or are partly correct.

There are (and going to be) hundreds of competitors mass producing test kits and within 1 year they will all be pregnancy test kits fighting for shelf space, just like pregnancy tests.

University of Aberdeen is being used to test the SARS-CoV-2 virus on normal Labskin and on very specifically grown Labskin that mimics the soft tissue of the nasal mucosa to identify ingredients that kill the virus in the nasal and Oral cavity areas. This is the dental part of the RNS.

Aptamers, that are grown to only capture the target pathogen (SARS-CoV-2, Norovirus, Enterovirus, E. Coli bacteria etc) are being coated onto the surface of our nano-photonic surface of the RAWTest cartridge. The cartridges will be 1 and 4 units (they can be one pathogen target, a multiple of the same pathogen target or a variety of targets). These are designed for the purpose of detecting the pathogen targets in water (drinking and wastewater).

The business model of Integumen is collaboration, cooperation, not competition. This is illustrated by participants in the ecowaterOS consortia. I have mentioned in a recent video that Rinocloud, Labskin, Nimbus, Modern Water are a solution, but even together they are a small part of a global solution to test and even predict hotspot breakouts before they spread into the community.

To produce high volume requires OEM producers of the electronic equipment. That is just another participant in an ever growing consortium.

The business model establishes a sales, marketing and distribution that it controls and dominates in the sectors where it already operates in. Modern Water has a presence across the world with thousands of existing units and customers on all continents. Owned, controlled and dominates with a 30 year old Brand, respected in water contamination detection

That is the growth strategy and I am pleased that most of you have read, researched and understand what is being built.

There are shareholders who are traders and there is no means to address the volatility of the share price in the short term. There is a big picture project here, and that takes time. So for me, as a shareholder, investor, lender, management and board member, I am in this for the lifetime of the project, not the timing of a day trade. I have respect for both trader and long time shareholder.

Good luck to everyone

@DaveJi All news is official :) It's the unofficial news you need to look out for, as it is usually fake :)

@Kingkongrider. The system is currently being tested for and being purposely built to satisfy a huge demand for real-time alerts for pathogenic virus and bacteria in water and wastewater. Any flow of water through the unit has the potential to detect contaminants that are in the "water". It does not distinguish where the source of that water comes from.

The issue is whether the use of pathogen capturing molecules, that we use (and there are many available to us) have the ability to survive in the disinfection methods in water being tested. So to answer your question, yes it is possible.

@Lazypunter I appreciate the support and vote of confidence

@Bronxville China will be fine for us as I have been involved with China since 2003 and offices of MWG have been there since 2011.

Legislation already exists and in particular China is fast becoming critical to accelerating growth due to COVID19 See this thread on Twitter https://twitter.com/gjbrandon/status/1275808835811389441?s=20

@Sloppy that is a good article and as it comes from a peer reviewed study adds serious credibility to what we have known for months. Also yesterday's $4.4 billion loss for Carnival Cruise Group is testement to the desperation this and other tourist sectors are in.

Countries with the highest proportion of GDP that rely on tourism also have the highest unemployment because the tourist sector is hit so badly. Real-time detection is critical to providing security. What is the point of a track and trace if you only know after 3 days that a hotel or cruise ship has Coronavirus, when everyone has disembarked in multiple ports or guests flying home spreading the virus across borders, even continents again. Roll-on the roll out of Microtox AI which was partly begun with the launch gnof the MWG AI division yesterday as part of the Integumen data management system from ecowaterOS

@daygrow I would ask you to give the team, who are transferring much of the data over from the old site and working on the integration of the Mandarin site too, a little time to complete. They felt after 8 weeks that it was necessary to roll out and complete the front end as they move across.

No Proactive Investor video, but a Broker Note will shed more light on this news later when it is released.

@daygrow. You do have to keep up. We won the New Product Award. This is a Social Impact Award for the impact our technology has made. It also shows what tereitories the core revenue streams of MWG come from and where that value is understood and respected.

Thanks Stuart. Indeed we had been getting some stick about the website, but it was not about the website, it was the AI system integration designed to allow data from Microtox units with incorporated communications units to transmit fully encrypted data back to Modern Water’s data servers. This forms the core of the pathogen identification system which will be retrofitted to each unit. This is like what SKIN did for Labskin by adding AI it increased revenues per client and added a whole new layer of revenue from higher value added virtual services, including predictive modelling. The same system has been incorporated here to create a MicrotoxAI division.

By the way the new website looks great too, with back end fully integrated moving the company sales fully online to meet any limitations of COVID19 restricted travelling for staff.

@Stu. Well not much anyway

When you consider the that public use of high powered dryers has the capability to transmit pathogens around the wash area, this is one piece of equipment that will be removed for public health safety.

@alwaysone it would simple for me to just ignore your departure, but I must stress that depreciation and write-offs are due to disposal of non-performing assets that were part of the original Integumen that management indicated in late August 2018 that were necessary to dispose of. There was a lot wrong with the business model which had to be changed from selling consumer oral care, skincare products and skin test kits to research labs of skin care companies.

They were one off and after the Rinocloud acquision, the business model is 100% business to business focused on recurring revenues from digital and physical services.

The risk level of any investor is important to making decisions to participate for medium to long term and a business is not built overnight, so we will be here if and when you decide we are doing right by your portfolio.

All the best